Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6026099 | 0.97 | NAMPT (0.54) | NAMPTPTPN1PTPN2HDAC1KMT2A | |
| SCHEMBL6026103 | 0.94 | HDAC1 (0.52) | NAMPTPTPN1PTPN2HDAC1KMT2A | |
| SCHEMBL6028360 | 0.90 | PTPN1 (0.62) | PTPN1PTPN2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6028790 | 0.90 | PTPN1 (0.62) | PTPN1PTPN2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL14305032 | 0.90 | PTPN1 (0.62) | PTPN1PTPN2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL14311202 | 0.90 | PTPN1 (0.62) | PTPN1PTPN2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6028319 | 0.84 | PTPN1 (0.54) | NAMPTPTPN1PTPN2ALDH1A1SMN1; SMN2 | |
| SCHEMBL6029160 | 0.84 | PTPN1 (0.54) | NAMPTPTPN1PTPN2ALDH1A1SMN1; SMN2 | |
| SCHEMBL6887046 | 0.84 | PTPN1 (0.54) | PTPN1PTPN2KMT2AALDH1A1MAPT | |
| SCHEMBL6028361 | 0.84 | PTPN1 (0.54) | PTPN1PTPN2KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613310-A1 | IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS | Avanir Pharmaceuticals (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20040229927-A1 | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | AVANIR PHARMACEUTICALS | 2004-11-18 | — | — | US | disclosed |
| WO-2004091610-A1 | IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS | AVANIR PHARMACEUTICALS (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229927-A1 | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | ICOS, TSLP, IKZF3 | NAMPT 2391/4885PTPN1 2513/4885PTPN2 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.